On the other hand, Ezh2-deficient mouse models have demonstrated the requirement of EZH2 for developing myeloid malignancies, including MLL-AF9 AML, in which Ezh2 mutation or deletion causes a loss of LSCs and an increase in differentiation [59]. The gene discussed is KMT2A; the disease is acute myeloid leukemia.